CAN-106

DB18389InvestigationalProtein Based Therapies

CAN-106 a novel, long-acting monoclonal antibody directed against human complement C5.

Mechanism: Pharmacologically active on Complement C5
Curator reviewed
Also known as: Immunoglobulin G [27-histidine,57-histidine,253-tyrosine,255- threonine,257-glutamic acid], anti-(human complement C5) (human monoclonal CAN106 hybrid y2-chain CH1-hinge region/y4-chain CH2- CH3 region), disulfide with human monoclonal CAN106 Kappa-chain, dimer
Code names: CAN-106

Resolves to

Compound

Targets

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with CAN-106, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.